Andere Sprachen Harmony Biosciences Holdings, Inc.

Aktien

A2QBSF

US4131971040

HRMY

Markt geschlossen - Nasdaq Andere Börsenplätze 22:00:00 07.06.2024			% 5 Tage	% 1. Jan.
30,5 ^USD	-0,07 %		+3,74 %	-5,57 %

05.06.	HARMONY Biosciences präsentiert positive Daten für Pitolisant bei der Behandlung von übermäßiger Tagesmüdigkeit und FATIGUE bei Myotonischer Dystrophie Typ 1	CI
03.05.	Harmony Biosciences Holdings, Inc. ernennt Kumar Budur zum Executive Vice President und Chief Medical & Scientific Officer	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

HARMONY BIOSCIENCES PRESENTS POSITIVE DATA FOR PITOLISANT IN THE TREATMENT OF EXCESSIVE DAYTIME SLEEPINESS AND FATIGUE IN MYOTONIC DYSTROPHY TYPE 1	05.06.
HARMONY Biosciences Presents Positive Data for Pitolisant in the Treatment of Excessive Daytime Sleepiness and FATIGUE in Myotonic Dystrophy Type 1	05.06.
HARMONY BIOSCIENCES TO PARTICIPATE IN GOLDMAN SACHS 45th ANNUAL GLOBAL HEALTHCARE CONFERENCE	28.05.
Harmony Biosciences Holdings, Inc. Appoints Kumar Budur as Executive Vice President and Chief Medical & Scientific Officer	03.05.
Harmony Biosciences Reports Strong First Quarter Financial Results and Acceleration of Its Growth Strategy	01.05.
Harmony Biosciences Acquires Epygenix Therapeutics; Shares Rise	30.04.
Tranche Update on Harmony Biosciences Holdings, Inc.'s Equity Buyback Plan announced on October 31, 2023.	30.04.
Harmony Biosciences Holdings, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	30.04.
Earnings Flash (HRMY) HARMONY BIOSCIENCES Posts Q1 EPS $0.88, vs. Street Est of $0.78	30.04.
Harmony Biosciences Reports Strong First Quarter Financial Results and Acceleration of Its Growth Strategy; Advances Pitolisant Franchise to Extend Revenue Potential Beyond 2040; Strenghtens Sleep/Wake Leadership and Diversifies Into Rare Epilepsy	30.04.
Harmony Biosciences Holdings, Inc. Reiterates Revenue Guidance for the Year 2024	30.04.
Harmony Biosciences Acquires Epygenix Therapeutics, Inc., Adding Late-Stage Epilepsy Franchise to Growing Pipeline of Innovative CNS Assets	30.04.
HARMONY BIOSCIENCES TO REPORT FIRST QUARTER 2024 FINANCIAL RESULTS ON APRIL 30, 2024	16.04.
HARMONY BIOSCIENCES ANNOUNCES EXCLUSIVE AGREEMENT TO DEVELOP AND COMMERCIALIZE TPM-1116, A HIGHLY POTENT AND SELECTIVE ORAL OREXIN-2 RECEPTOR AGONIST	12.04.
Harmony Biosciences, Bioprojet Enter Licensing Deal for Sleep Disorder Therapy	11.04.
Harmony Biosciences Begins Phase 3 Trial of Pitolisant to Treat Prader-Willi Syndrome Symptoms	03.04.
HARMONY BIOSCIENCES INITIATES GLOBAL PHASE 3 REGISTRATIONAL TRIAL (TEMPO STUDY) OF PITOLISANT IN PATIENTS WITH PRADER-WILLI SYNDROME	03.04.
Harmony Biosciences Initiates Global Phase 3 Registrational Trial (Tempo Study) of Pitolisant in Patients with Prader-Willi Syndrome	03.04.
HARMONY BIOSCIENCES TO PARTICIPATE IN 23RD ANNUAL NEEDHAM VIRTUAL HEALTHCARE CONFERENCE	26.03.
Harmony Biosciences Holdings Insider Sold Shares Worth $383,328, According to a Recent SEC Filing	19.03.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Harmony Biosciences Holdings, Inc.

Aktien

A2QBSF

US4131971040

HRMY

Andere Sprachen

Filter